In one paragraphArticle in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Ana Zamora-CánovasServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.
Ana Marín-QuílezServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.ORCID 0000-0002-2005-1919 Lorena Díaz-AjenjoInstituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer, IBMCC-CSIC, Universidad de Salamanca (USAL), 37007 Salamanca, Spain.
Ana Sánchez-FuentesServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.ORCID 0000-0002-4656-4771 Pedro Luis Gómez-GonzálezServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.ORCID 0009-0007-6103-7236 Marilena CrescenteCentre for Immunobiology, Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London E1 2AD, UK.
Nuria Fernández-MosteirínServicio de Hematología, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
José PadillaServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.ORCID 0000-0003-1599-7870 José Ramón González-PorrasInstituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer, IBMCC-CSIC, Universidad de Salamanca (USAL), 37007 Salamanca, Spain.ORCID 0000-0003-3266-7996 Rocío BenitoInstituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer, IBMCC-CSIC, Universidad de Salamanca (USAL), 37007 Salamanca, Spain.ORCID 0000-0001-9781-4198 María Luisa LozanoServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.ORCID 0000-0003-3148-7037 José María BastidaInstituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer, IBMCC-CSIC, Universidad de Salamanca (USAL), 37007 Salamanca, Spain.ORCID 0000-0002-8007-3909 José Rivera PozoServicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, 30003 Murcia, Spain.ORCID 0000-0003-4225-6840 Funding
Fundación Séneca - Agencia de Ciencia y Tecnología de la Región de Murcia 21920/PI/22Gerencia Regional de Salud GRS2551/A/22, GRS2907/A1/2023, GRS2727/A1/23ISCIII&EU PI23/00624; PI24/01458, PMP21/00052Sociedad Española de Trombosis y Hemostasia Ayuda Grupos de trabajo (GEAPC)
6 · The paper itselfAbstract
Inherited platelet function disorders (IPFDs) are rare diseases caused by defects in platelet surface receptors, enzymes, granules, or signaling proteins. In humans, GPVI and P2Y12 deficiency cause autosomal recessive bleeding disorders, while TBXAS1 deficiency is related to Ghosal hematodiaphyseal dysplasa, a rare autosomal recessive disorder characterized by increased long bone density and platelet dysfunction without bleeding. To date, at least 20 patients have been identified with molecular defects in
Indexed as
HemorrhagePlatelet Membrane GlycoproteinsReceptors, Purinergic P2Y12AdultBlood PlateletsFemaleHumansMaleMutation, MissenseP2RY12 protein, humanPlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VIReceptors, Purinergic P2Y12bleedingGPVI deficiencyinherited platelet function disordersIPFDP2Y12 deficiencyTBXAS1 deficiency
Identifiers
PMID41463295
PMCPMC12730773
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390